• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MCK

    McKesson Corporation

    Subscribe to $MCK
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

    IPO Year:

    Exchange: NYSE

    Website: mckesson.com

    Peers

    $HSIC
    $BDX
    $CAH

    Recent Analyst Ratings for McKesson Corporation

    DatePrice TargetRatingAnalyst
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    12/14/2023$502.00Equal Weight
    Wells Fargo
    3/31/2023$420.00Buy
    Citigroup
    8/22/2022Overweight
    Morgan Stanley
    See more ratings

    McKesson Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on July 1, 2025, to stockholders of record on June 2, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read

      5/1/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC

      Announces fourth quarter and full year fiscal 2025 earnings release date McKesson Corporation (NYSE:MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, for about $850 million. PRISM physicians will retain an approximate 20% interest. The acquisition enables McKesson to develop a leading retinal and ophthalmology platform and expand McKesson's differentiated value proposition, clinical services a

      4/2/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Reports Fiscal 2025 Third Quarter Results and Raises Full Year Adjusted EPS Guidance

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 5th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at

      2/5/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Advances Specialty Leadership; Signs Agreement to Acquire Controlling Interest in PRISM Vision Holdings, LLC

      Acquisition enhances McKesson's capabilities as a national partner in retina and ophthalmology care McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC (PRISM Vision), a premier provider of general ophthalmology and retina management services, from Quad-C. McKesson will purchase an 80% interest for approximately $850 million. PRISM Vision physicians will continue to retain a 20% interest in PRISM Vision. "The acquisition of PRISM Vision will allow McKesson to build on our leadership in community practice and specialty solutions, while building a platform to serve the high-growth area of r

      2/4/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on April 1, 2025, to stockholders of record on March 3, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and r

      1/30/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Divestiture of Canada-Based Rexall and Well.ca Businesses

      McKesson Corporation (NYSE:MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This transaction enables the Company to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms. Additional details related to the divestiture can be found on the company's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biop

      12/31/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Announces Third Quarter Fiscal 2025 Earnings Release Date and Participation in January Conference

      McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. The live webcast for each event will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Co

      12/30/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, November 6th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at

      11/6/24 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com an

      10/31/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    McKesson Corporation Financials

    Live finance-specific insights

    See more
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on July 1, 2025, to stockholders of record on June 2, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read

      5/1/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC

      Announces fourth quarter and full year fiscal 2025 earnings release date McKesson Corporation (NYSE:MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, for about $850 million. PRISM physicians will retain an approximate 20% interest. The acquisition enables McKesson to develop a leading retinal and ophthalmology platform and expand McKesson's differentiated value proposition, clinical services a

      4/2/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Reports Fiscal 2025 Third Quarter Results and Raises Full Year Adjusted EPS Guidance

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 5th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at

      2/5/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on April 1, 2025, to stockholders of record on March 3, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and r

      1/30/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Announces Third Quarter Fiscal 2025 Earnings Release Date and Participation in January Conference

      McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. The live webcast for each event will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Co

      12/30/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, November 6th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at

      11/6/24 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com an

      10/31/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Announces Second Quarter Fiscal 2025 Earnings Release Date

      McKesson Corporation (NYSE:MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, ph

      9/23/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Reports Fiscal 2025 First Quarter Results

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i

      8/7/24 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    McKesson Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/13/24 5:09:38 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      1/25/24 1:48:52 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/10/22 8:27:59 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/16/21 1:31:18 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/10/21 11:28:19 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    McKesson Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho resumed coverage on McKesson with a new price target

      Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

      12/4/24 7:43:38 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

      11/7/24 6:29:13 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously

      9/24/24 8:19:53 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Leerink Partners reiterated coverage on McKesson with a new price target

      Leerink Partners reiterated coverage of McKesson with a rating of Outperform and set a new price target of $665.00 from $670.00 previously

      9/5/24 11:05:08 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Mizuho reiterated coverage on McKesson with a new price target

      Mizuho reiterated coverage of McKesson with a rating of Neutral and set a new price target of $570.00 from $540.00 previously

      8/8/24 9:46:42 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Leerink Partners initiated coverage on McKesson with a new price target

      Leerink Partners initiated coverage of McKesson with a rating of Outperform and set a new price target of $600.00

      2/26/24 8:04:31 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Barclays initiated coverage on McKesson with a new price target

      Barclays initiated coverage of McKesson with a rating of Overweight and set a new price target of $537.00

      1/3/24 8:00:01 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Wells Fargo initiated coverage on McKesson with a new price target

      Wells Fargo initiated coverage of McKesson with a rating of Equal Weight and set a new price target of $502.00

      12/14/23 7:05:14 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Citigroup initiated coverage on McKesson with a new price target

      Citigroup initiated coverage of McKesson with a rating of Buy and set a new price target of $420.00

      3/31/23 7:19:03 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Morgan Stanley resumed coverage on McKesson

      Morgan Stanley resumed coverage of McKesson with a rating of Overweight

      8/22/22 8:52:42 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    McKesson Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Tyler Brian S. sold $5,684,059 worth of shares (8,962 units at $634.24), decreasing direct ownership by 17% to 42,741 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      3/7/25 3:30:44 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SVP, Controller & CAO Rutledge Napoleon B Jr converted options into 786 shares and covered exercise/tax liability with 243 shares, increasing direct ownership by 28% to 2,515 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      3/3/25 4:49:22 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Tyler Brian S. sold $5,591,664 worth of shares (8,961 units at $624.00), decreasing direct ownership by 15% to 51,703 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      3/3/25 4:48:46 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • EVP and Chief Legal Officer Lau Michele sold $188,760 worth of shares (312 units at $605.00), decreasing direct ownership by 10% to 2,808 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      2/26/25 2:31:43 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Tyler Brian S. sold $5,358,588 worth of shares (8,961 units at $597.99), decreasing direct ownership by 13% to 60,664 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      2/24/25 11:17:06 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Tyler Brian S. sold $5,382,514 worth of shares (8,961 units at $600.66), decreasing direct ownership by 11% to 69,625 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      2/18/25 12:04:16 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • EVP & Chief HR Officer Smith Leann B sold $114,603 worth of shares (188 units at $609.59), decreasing direct ownership by 15% to 1,051 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      2/13/25 4:55:56 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • EVP and Chief Legal Officer Lau Michele converted options into 4,747 shares and covered exercise/tax liability with 1,627 shares (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      2/12/25 2:45:11 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • EVP & Chief HR Officer Smith Leann B converted options into 507 shares and covered exercise/tax liability with 132 shares, increasing direct ownership by 43% to 1,239 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      2/12/25 2:44:32 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Director Doughtie Lynne M

      4 - MCKESSON CORP (0000927653) (Issuer)

      2/10/25 3:09:08 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    McKesson Corporation Leadership Updates

    Live Leadership Updates

    See more
    • McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

      Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

      8/26/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

      10/4/23 4:05:00 PM ET
      $KRMD
      $MCK
      Medical/Dental Instruments
      Health Care
      Other Pharmaceuticals
    • Gentherm Announces Dr. Ken Washington as New Independent Director

      NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

      10/2/23 8:00:00 AM ET
      $AMZN
      $F
      $MCK
      $MDT
      Catalog/Specialty Distribution
      Consumer Discretionary
      Auto Manufacturing
      Other Pharmaceuticals
    • Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

      Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

      8/3/23 3:00:00 PM ET
      $BWAY
      $INSG
      $MCK
      $NNDM
      Medical/Dental Instruments
      Health Care
      Telecommunications Equipment
      Telecommunications
    • COMPREHENSIVE HEALTHCARE SYSTEMS ANNOUNCES APPOINTMENT OF NEW BOARD MEMBER AND CHIEF EXECUTIVE OFFICER

      CALGARY, AB, Jan. 25, 2022 /CNW/ - Comprehensive Healthcare Systems Inc. (TSXV:CHS) (the "Company" or "CHS"), an industry leader in Healthcare Benefits Administration software and services, is pleased to announce the appointment of Chris Cosgrove as the Company's new President and Chief Executive Officer ("CEO") and to its board of directors effective February 1, 2022.  Mr. Cosgrove has 25 years of management and leadership experience in the healthcare technology industry and will replace CHS founder, Dr. Hassan Mohaideen, who will continue in his role as Chairman of the board of directors (the "Board") and be appointed Chief Medical Officer of the Company. "With a proven track record of lea

      1/25/22 8:00:00 AM ET
      $CERN
      $GE
      $MCK
      Managed Health Care
      Health Care
      Consumer Electronics/Appliances
      Technology
    • Hercules Capital Announces the Appointment of Ms. Pam Randhawa to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021. Ms. Randhawa is a thought leader within the life sciences sector and an experienced industry executive, with more than 20 years of experience leading public and private companies, ranging from biotech, healthcare and sustainable solutions, through their various stages of growth. Ms. Randhawa will ser

      10/20/21 6:00:00 AM ET
      $HCXY
      $HTGC
      $MCK
      Investment Managers
      Finance
      Other Pharmaceuticals
      Health Care

    McKesson Corporation SEC Filings

    See more
    • McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MCKESSON CORP (0000927653) (Filer)

      5/8/25 4:06:16 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form 144 filed by McKesson Corporation

      144 - MCKESSON CORP (0000927653) (Subject)

      2/28/25 11:26:50 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form 144 filed by McKesson Corporation

      144 - MCKESSON CORP (0000927653) (Subject)

      2/25/25 9:51:41 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Amendment: McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K/A - MCKESSON CORP (0000927653) (Filer)

      2/5/25 4:27:38 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MCKESSON CORP (0000927653) (Filer)

      2/5/25 4:05:22 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by McKesson Corporation

      10-Q - MCKESSON CORP (0000927653) (Filer)

      11/7/24 4:09:20 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MCKESSON CORP (0000927653) (Filer)

      11/6/24 4:05:21 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - MCKESSON CORP (0000927653) (Filer)

      9/10/24 4:11:17 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form 424B5 filed by McKesson Corporation

      424B5 - MCKESSON CORP (0000927653) (Filer)

      9/6/24 5:09:42 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form FWP filed by McKesson Corporation

      FWP - MCKESSON CORP (0000927653) (Subject)

      9/5/24 4:30:33 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care